These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 21077700)

  • 1. Monitoring adverse events of the vaccination campaign against influenza A (H1N1) in the Netherlands.
    van Puijenbroek EP; Broos N; van Grootheest K
    Drug Saf; 2010 Dec; 33(12):1097-108. PubMed ID: 21077700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring adverse events of vaccines against Mexican flu.
    van Puijenbroek EP; van Grootheest AC
    Int J Risk Saf Med; 2011; 23(2):81-7. PubMed ID: 21673415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fever following immunization with influenza A (H1N1) vaccine in children: a survey-based study in the Netherlands.
    Broos N; van Puijenbroek EP; van Grootheest K
    Drug Saf; 2010 Dec; 33(12):1109-15. PubMed ID: 21077701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvanted A/H1N1 (2009) influenza vaccination during pregnancy: description of a prospective cohort and spontaneously reported pregnancy-related adverse reactions in the Netherlands.
    de Vries L; van Hunsel F; Cuppers-Maarschalkerweerd B; van Puijenbroek E; van Grootheest K
    Birth Defects Res A Clin Mol Teratol; 2014 Oct; 100(10):731-8. PubMed ID: 24706475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.
    Durrieu G; Palmaro A; Pourcel L; Caillet C; Faucher A; Jacquet A; Ouaret S; Perault-Pochat MC; Kreft-Jais C; Castot A; Lapeyre-Mestre M; Montastruc JL;
    Drug Saf; 2012 Oct; 35(10):845-54. PubMed ID: 22967189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of adverse events among healthcare workers following H1N1 Mass immunization in Ghana: a prospective study.
    Ankrah DN; Mantel-Teeuwisse AK; De Bruin ML; Amoo PK; Ofei-Palm CN; Agyepong I; Leufkens HG
    Drug Saf; 2013 Apr; 36(4):259-66. PubMed ID: 23508545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilance.
    Kurz X; Domergue F; Slattery J; Segec A; Szmigiel A; Hidalgo-Simon A
    Vaccine; 2011 Jun; 29(26):4378-87. PubMed ID: 21501644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience.
    Oosterhuis I; Scholl J; van Puijenbroek E; Kant A; van Hunsel F
    Drug Saf; 2023 Jan; 46(1):65-75. PubMed ID: 36350465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring the safety of influenza A (H1N1) vaccine using web-based intensive monitoring.
    Härmark L; van Hunsel F; Hak E; van Grootheest K
    Vaccine; 2011 Feb; 29(10):1941-7. PubMed ID: 21236235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations.
    Banzhoff A; Haertel S; Praus M
    Hum Vaccin; 2011 May; 7(5):539-48. PubMed ID: 21422814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring the safety of influenza A/H1N1 pandemic and seasonal vaccines in Morocco.
    Tebaa A; Benkirane R; Alj L; Cherkaoui I; Soulaymani-Bencheikh R
    Ther Adv Vaccines Immunother; 2022; 10():25151355221088157. PubMed ID: 35372783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of a robust infrastructure to monitor the safety of the pandemic A(H1N1) 2009 vaccination program in Taiwan.
    Huang WT; Chen WW; Yang HW; Chen WC; Chao YN; Huang YW; Chuang JH; Kuo HS
    Vaccine; 2010 Oct; 28(44):7161-6. PubMed ID: 20804804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Sex on the Incidence, Latency, Duration and Perceived Burden of Adverse Events Following Seasonal Influenza Vaccination in the Netherlands.
    Slingerland P; van Hunsel FPAM; Lieber T; van Balveren L; Duijster JW
    Drug Saf; 2023 Dec; 46(12):1323-1334. PubMed ID: 37882905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Reported adverse events following influenza vaccination].
    van Balveren-Slingerland L; Rümke HC; Kant AC
    Ned Tijdschr Geneeskd; 2014; 158():A6841. PubMed ID: 24518843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands.
    Kant A; Jansen J; van Balveren L; van Hunsel F
    Drug Saf; 2022 Apr; 45(4):319-331. PubMed ID: 35314943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of Influenza A H1N1pdm09 Vaccines: An Overview of Systematic Reviews.
    Juvet LK; Robertson AH; Laake I; Mjaaland S; Trogstad L
    Front Immunol; 2021; 12():740048. PubMed ID: 34777351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allergic adverse events following 2015 seasonal influenza vaccine, Victoria, Australia.
    Clothier HJ; Crawford N; Russell MA; Buttery JP
    Euro Surveill; 2017 May; 22(20):. PubMed ID: 28552101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands.
    van der Boor SC; Schmitz-de Vries ETJ; Smits D; Scholl JHG; Rolfes L; van Hunsel F
    Vaccine; 2023 Jun; 41(29):4319-4326. PubMed ID: 37286408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine safety.
    Labadie J
    Int J Risk Saf Med; 2011; 23(2):113-5. PubMed ID: 21673419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.